Windlas Biotech quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	248	210	+18.1%
EBITDA	26.7	26.5	+0.6%
EBITDA margin	10.8%	12.6%	−1.9 pts
Profit before tax	22.9	23.3	−1.4%
Net profit	17.7	17.7	−0.1%
EPS	₹8.46	₹8.43	+0.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	248	238	233	222	210	203	195	187	175	171	162	153	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	5.1	4.4	4.5	3.6	5.2	4.9	3.7	4.8	4.1	4.4	3.2	3.2
	253	243	238	226	215	208	199	192	179	176	165	156
	−13.5	3.8	−5.5	8.0	6.1	3.3	0.9	0.4	−2.3	2.1	−5.4	4.4
	182	142	140	136	119	112	134	127	118	105	105	86.4
	−16.0	1.6	8.6	−7.3	4.3	10.1	−13.7	−11.1	−6.8	0.5	1.7	5.1
	44.4	41.4	42.0	36.4	32.2	31.9	32.2	31.0	27.9	22.8	22.7	21.3
	1.7	1.5	1.3	1.0	1.1	1.3	1.5	1.1	0.5	0.3	0.3	0.3
	7.2	8.0	7.7	7.6	7.4	8.3	6.9	6.5	6.2	3.5	3.4	3.3
	24.3	24.8	23.2	20.4	21.6	20.0	17.4	16.6	17.0	19.3	17.5	16.8
	230	223	218	202	192	187	179	172	161	153	146	138
	26.7	25.2	24.4	28.6	26.5	25.5	24.6	23.0	20.9	21.9	20.3	18.7
	19.5	17.2	16.7	21.0	19.1	17.2	17.7	16.5	14.7	18.4	16.9	15.4
Profit
	22.9	20.2	19.9	23.6	23.3	20.8	20.0	20.3	18.3	22.6	19.8	18.3
	22.9	20.2	19.9	23.6	23.3	20.8	20.0	20.3	18.3	22.6	19.8	18.3
	6.4	4.8	4.5	5.9	5.6	4.6	3.9	5.1	4.6	4.5	4.5	4.4
	−1.1	−0.7	0.5	−0.1	0.0	−0.1	0.8	−0.5	0.2	1.1	0.2	−0.1
	5.3	4.1	5.0	5.8	5.6	4.5	4.7	4.6	4.8	5.6	4.7	4.3
	17.7	16.0	15.0	17.8	17.7	16.3	15.2	15.7	13.5	16.9	15.1	14.0
	17.7	16.0	15.0	17.8	17.7	16.3	15.2	15.7	13.5	16.9	15.1	14.0
	−0.0	0.1	0.2	−0.2	0.0	0.2	−0.0	−0.2	−0.5	0.0	0.0	0.0
	17.6	16.1	15.1	17.6	17.7	16.5	15.2	15.4	13.0	17.0	15.1	14.1
Per share
	₹8.46	₹7.60	₹7.09	₹8.48	₹8.43	₹7.77	₹7.29	₹7.49	₹6.47	₹8.15	₹7.26	₹6.75
	₹8.32	₹7.50	₹7.03	₹8.40	₹8.34	₹7.69	₹7.21	₹7.43	₹6.44	₹8.12	₹7.26	₹6.75
Other comprehensive income — detail
	−0.0	0.1	0.2	−0.2	0.0	0.2	—	—	—	—	—	—
	−0.1	0.1	0.2	−0.2	0.0	0.2	−0.0	−0.3	−0.6	0.0	0.0	0.0
	−0.0	0.0	0.1	−0.1	0.0	0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.1	−0.2	0.0	0.0	0.0
Per share — as-filed variants
	₹8.46	₹7.60	₹7.09	₹8.48	₹8.43	₹7.77	₹7.29	₹7.49	₹6.47	₹8.15	₹7.26	₹6.75
	₹8.32	₹7.50	₹7.03	₹8.40	₹8.34	₹7.69	₹7.21	₹7.43	₹6.44	₹8.12	₹7.26	₹6.75
Regulatory disclosures — filed alongside, not part of the P&L
	—	6.7	—	14.1	—	5.3	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	95.4	91.4	89.6	85.4	80.4	77.5	74.2	70.6	65.7	64.1	60.6	56.8
	38.4%	38.3%	38.4%	38.4%	38.3%	38.2%	38.0%	37.7%	37.5%	37.4%	37.3%	37.2%
Adjusted (ex-exceptional items) — derived
	22.9	20.2	19.9	23.6	23.3	20.8	20.0	20.3	18.3	22.6	19.8	18.3
	17.7	16.0	15.0	17.8	17.7	16.3	15.2	15.7	13.5	16.9	15.1	14.0
	₹8.46	₹7.60	₹7.09	₹8.48	₹8.43	₹7.77	₹7.29	₹7.49	₹6.47	₹8.15	₹7.26	₹6.75

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersHESTERBIO INDOCO SAIPARENT SYNCOMF PANACEABIO NGLFINE HIKAL JAGSNPHARMMcap ₹1,876 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	152.7	162.2	171.3	175.2	187.0	195.0	202.7	210.1	222.4	233.1	238.5	248.1
Other Income	3.2	3.2	4.4	4.1	4.8	3.7	4.9	5.2	3.6	4.5	4.4	5.1
Total Income	155.9	165.4	175.7	179.3	191.8	198.8	207.6	215.3	226.0	237.6	242.9	253.2
Expenses
+ Cost of Materials Consumed	4.4	-5.4	2.1	-2.3	0.4	0.9	3.3	6.1	8.0	-5.5	3.8	-13.5
+ Purchases of Stock-in-Trade	86.4	105.3	104.6	118.5	127.2	133.6	111.8	119.3	136.3	140.4	141.7	182.2
+ Changes in Inventories	5.1	1.7	0.5	-6.8	-11.1	-13.7	10.1	4.3	-7.3	8.6	1.6	-16.0
+ Employee Benefit Expense	21.3	22.7	22.8	27.9	31.0	32.2	31.9	32.2	36.4	42.0	41.4	44.4
+ Finance Costs	0.3	0.3	0.3	0.5	1.1	1.5	1.3	1.1	1.0	1.3	1.5	1.7
+ Depreciation & Amortisation	3.3	3.4	3.5	6.2	6.5	6.9	8.3	7.4	7.6	7.7	8.0	7.2
+ Other Expenses	16.8	17.5	19.3	17.0	16.6	17.4	20.0	21.6	20.4	23.2	24.8	24.3
Total Expenses	137.6	145.6	153.2	161.0	171.6	178.8	186.8	192.1	202.5	217.7	222.7	230.3
EBITDA	18.7	20.3	21.9	20.9	23.0	24.6	25.5	26.5	28.6	24.4	25.2	26.7
EBIT	15.4	16.9	18.4	14.7	16.5	17.7	17.2	19.1	21.0	16.7	17.2	19.5
Profit
PBT before Exceptional Items	18.3	19.8	22.6	18.3	20.3	20.0	20.8	23.3	23.6	19.9	20.2	22.9
Pretax Income	18.3	19.8	22.6	18.3	20.3	20.0	20.8	23.3	23.6	19.9	20.2	22.9
+ Current Tax	4.4	4.5	4.5	4.6	5.1	3.9	4.6	5.6	5.9	4.5	4.8	6.4
+ Deferred Tax	-0.1	0.2	1.1	0.2	-0.5	0.8	-0.1	0.0	-0.1	0.5	-0.7	-1.1
Tax Expense	4.3	4.7	5.6	4.8	4.6	4.7	4.5	5.6	5.8	5.0	4.1	5.3
Net Income	14.0	15.1	16.9	13.5	15.7	15.2	16.3	17.7	17.8	15.0	16.0	17.7
+ Net Income — Continuing Ops	14.0	15.1	16.9	13.5	15.7	15.2	16.3	17.7	17.8	15.0	16.0	17.7
+ Other Comprehensive Income	0.0	0.0	0.0	-0.5	-0.2	-0.0	0.2	0.0	-0.2	0.2	0.1	-0.0
Total Comprehensive Income	14.1	15.1	17.0	13.0	15.4	15.2	16.5	17.7	17.6	15.1	16.1	17.6
Per Share
Basic EPS	6.75	7.26	8.15	6.47	7.49	7.29	7.77	8.43	8.48	7.09	7.60	8.46
Diluted EPS	6.75	7.26	8.12	6.44	7.43	7.21	7.69	8.34	8.40	7.03	7.50	8.32
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.2	0.0	-0.2	0.2	0.1	-0.0
+ Items NOT to be Reclassified to P&L	0.0	0.0	0.0	-0.6	-0.3	-0.0	0.2	0.0	-0.2	0.2	0.1	-0.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.1	0.0	-0.1	0.1	0.0	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	0.0	-0.2	-0.1	-0.0	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.75	7.26	8.15	6.47	7.49	7.29	7.77	8.43	8.48	7.09	7.60	8.46
Diluted EPS — Continuing Operations	6.75	7.26	8.12	6.44	7.43	7.21	7.69	8.34	8.40	7.03	7.50	8.32
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	5.3	—	14.1	—	6.7	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	56.8	60.6	64.1	65.7	70.6	74.2	77.5	80.4	85.4	89.6	91.4	95.4
Gross Margin %	37.20	37.34	37.44	37.54	37.74	38.04	38.24	38.25	38.42	38.44	38.34	38.44
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	18.3	19.8	22.6	18.3	20.3	20.0	20.8	23.3	23.6	19.9	20.2	22.9
Net Income Adj (tax-effected)	14.0	15.1	16.9	13.5	15.7	15.2	16.3	17.7	17.8	15.0	16.0	17.7
EPS Adj	6.75	7.26	8.15	6.47	7.49	7.29	7.77	8.43	8.48	7.09	7.60	8.46
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	10.4	10.4	10.4	10.5	10.5	10.5	10.5	10.5	10.5	10.5	10.6	10.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Windlas Biotech quarterly results

Windlas Biotech (NSE: WINDLAS) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Standalone net profit was ₹17.7 crore, down 0.1% from ₹17.7 crore in Q1 FY26 and up 10.2% from ₹16 crore in Q4 FY26. Revenue from operations was ₹248 crore, up 18.1% year on year and up 4.0% from the previous quarter.

Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · standalone

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹17.7 Cr−0.1% vs Q1 FY26+10.2% vs Q4 FY26
Q1 FY27 revenue: ₹248 Cr+18.1% vs Q1 FY26+4.0% vs Q4 FY26
Q1 FY27 operating margin: 7.8%−1.2 pts vs Q1 FY26+0.6 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹17.8 CrRevenue ₹222 Cr
Q1 FY27 EPS (basic): ₹8.46

Questions

When will Windlas Biotech announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 6 November 2025.

What will Windlas Biotech's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when standalone net profit was ₹17.8 crore and revenue from operations ₹222 crore. The latest quarter, Q1 FY27, had a net profit of ₹17.7 crore and revenue of ₹248 crore.

What were Windlas Biotech's Q1 FY27 results?

Standalone net profit was ₹17.7 crore, down 0.1% from ₹17.7 crore in Q1 FY26 and up 10.2% from ₹16 crore in Q4 FY26. Revenue from operations was ₹248 crore, up 18.1% year on year and up 4.0% from the previous quarter.

How has Windlas Biotech's profit changed over the last four quarters?

Net profit by quarter: ₹17.8 crore in Q2 FY26, ₹15 crore in Q3 FY26, ₹16 crore in Q4 FY26 and ₹17.7 crore in Q1 FY27. That is ₹66.4 crore over the four quarters, up 2.4% from ₹64.8 crore in the four quarters before. Revenue from operations: ₹222 crore, ₹233 crore, ₹238 crore and ₹248 crore.

What was Windlas Biotech's net profit in FY26?

Standalone net profit was ₹66.4 crore in FY26 (April 2025–March 2026), up 9.5% from ₹60.6 crore in FY25. It was ₹58.1 crore in FY24 and ₹42.6 crore in FY23: up 55.8% over three years, 15.9% a year on average.

What was Windlas Biotech's revenue in FY26?

Revenue from operations was ₹904 crore in FY26 (April 2025–March 2026), up 19.0% from ₹760 crore in FY25. It was ₹631 crore in FY24 and ₹513 crore in FY23: up 76.2% over three years, 20.8% a year on average.

Where do these Windlas Biotech figures come from?

From Windlas Biotech's own standalone results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Standalone figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.